Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 9072 Long-term Safety in Schizophrenia
NCT01626456Phase 3Completed
- Sponsor
- Alkermes
- Start
- Jun 2012
- Primary completion
- Apr 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of aripiprazole lauroxil in schizophrenia, sponsored by Alkermes. Started Jun 2012; status: completed.
02
Drugs
aripiprazole lauroxil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01626456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01626456.